I will be attending BioEurope in November and making a presentation at the international Biotech Showcase conference. These business development meetings are aimed at engaging pharma companies who are interested in potentially partnering AD-114 and the i-body platform.
The Company remains focused on executing our manufacturing, pre-clinical testing and Phase I clinical trial program of AD-114 and submitting the new data to the US FDA in early FY2017 for orphan drug designation.
AdAlta calendar for the remainder of 2016 and early 2017
Additional AD-114 IPF fibrosis data
Hypertrophic scarring animal results for AD-114
Evaluation of AD-114 with IPF clinicians Alfred Hospital
Data available from AD-114 NASH animal studies
AD-114 materials manufactured and available for toxicology testing
Presentation at Biotech Showcase, San Francisco
Orphan Drug Designation (US FDA)
1AD Price at posting:
19.0¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)